Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice

PLoS Neglected Tropical Diseases

Volumn 10, Issue 2, 2016, Pages

  Bassi, Maria R ^a   Larsen, Mads A B ^a   Kongsgaard, Michael ^a   Rasmussen, Michael ^a   Buus, Søren ^a   Stryhn, Anette ^a   Thomsen, Allan R ^a   Christensen, Jan P ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; NONSTRUCTURAL PROTEIN 3; VIRUS ANTIGEN; VIRAL PROTEIN; VIRUS ANTIBODY; YELLOW FEVER VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; IMMUNIZATION; IMMUNOASSAY; MOUSE; NONHUMAN; SPLEEN CELL; TRANSGENE; VACCINATION; VIRAL PLAQUE ASSAY; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS REPLICATION; YELLOW FEVER; YELLOW FEVER VIRUS; YF 17D VIRUS; ADENOVIRIDAE; ANIMAL; C57BL MOUSE; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; VIROLOGY;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED C57BL; VACCINATION; VIRAL PROTEINS; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84959475306     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004464     Document Type: Article

References (39)

1. Monath TP, Yellow fever vaccine. Expert Rev Vaccines2005;4: 553–574. 16117712
2. Theiler M, Smith HH, The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med1937;65: 787–800. 19870634
3. Theiler M, Smith HH, The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J Exp Med1937;65: 767–786. 19870633
4. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'age-Stehr J, Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol1998;56: 159–167. 9746073
5. Barrett AD, Teuwen DE, Yellow fever vaccine—how does it work and why do rare cases of serious adverse events take place?Curr Opin Immunol2009;21: 308–313. doi: 10.1016/j.coi.2009.05.01819520559
6. Jennings AD, Gibson CA, Miller BR, Mathews JH, Mitchell CJ, et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis1994;169: 512–518. 7908925
7. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet2001;358: 121–122. 11463415
8. Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet2001;358: 91–97. 11463409
9. Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet2001;358: 98–104. 11463410
10. Galler R, Pugachev KV, Santos CL, Ocran SW, Jabor AV, et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology2001;290: 309–319. 11883195
11. Maciel M, Jr.Cruz FS, Cordeiro MT, da Motta MA, Cassemiro KM, et al. A DNA vaccine against yellow fever virus: development and evaluation. PLoS Negl Trop Dis2015;9: e0003693. doi: 10.1371/journal.pntd.000369325875109
12. Barefoot B, Thornburg NJ, Barouch DH, Yu JS, Sample C, et al. Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine2008;26: 6108–6118. doi: 10.1016/j.vaccine.2008.09.00718809447
13. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature2002;415: 331–335. 11797011
14. Holst PJ, Sorensen MR, Mandrup Jensen CM, Orskov C, Thomsen AR, et al. MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines. J Immunol2008;180: 3339–3346. 18292559
15. Bett AJ, Dubey SA, Mehrotra DV, Guan L, Long R, et al. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans. Vaccine2010;28: 7881–7889. doi: 10.1016/j.vaccine.2010.09.07920937317
16. Mikkelsen M, Holst PJ, Bukh J, Thomsen AR, Christensen JP, Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. J Immunol2011;186: 2355–2364. doi: 10.4049/jimmunol.100187721257961
17. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature2003;424: 681–684. 12904795
18. Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med2014;20: 1126–1129. doi: 10.1038/nm.370225194571
19. Barnes E, Folgori A, Capone S, Swadling L, Aston S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med2012;4: 115ra1. doi: 10.1126/scitranslmed.300315522218690
20. Jensen S, Steffensen MA, Jensen BA, Schluter D, Christensen JP, et al. Adenovirus-based vaccine against Listeria monocytogenes: extending the concept of invariant chain linkage. J Immunol2013;191: 4152–4164. doi: 10.4049/jimmunol.130129024043891
21. Schuldt NJ, Amalfitano A, Malaria vaccines: focus on adenovirus based vectors. Vaccine2012;30: 5191–5198. doi: 10.1016/j.vaccine.2012.05.04822683663
22. Bassi MR, Kongsgaard M, Steffensen MA, Fenger C, Rasmussen M, et al. CD8+ T cells complement antibodies in protecting against yellow fever virus. J Immunol2015;194: 1141–1153. doi: 10.4049/jimmunol.140260525539816
23. Nansen A, Jensen T, Christensen JP, Andreasen SO, Ropke C, et al. Compromised virus control and augmented perforin-mediated immunopathology in IFN-gamma-deficient mice infected with lymphocytic choriomeningitis virus. J Immunol1999;163: 6114–6122. 10570301
24. Becker TC, Noel RJ, Coats WS, Gomez-Foix AM, Alam T, et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol1994;43Pt A: 161–189. 7823861
25. Cobbold S, Martin G, Waldmann H, Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo. Transplantation1986;42: 239–247. 3529524
26. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H, Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature1984;312: 548–551. 6150440
27. van der Most RG, Harrington LE, Giuggio V, Mahar PL, Ahmed R, Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology2002;296: 117–124. 12036323
28. Holst PJ, Bartholdy C, Stryhn A, Thomsen AR, Christensen JP, Rapid and sustained CD4(+) T-cell-independent immunity from adenovirus-encoded vaccine antigens. J Gen Virol2007;88: 1708–1716. 17485530
29. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature2003;421: 852–856. 12594515
30. Sun JC, Williams MA, Bevan MJ, CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol2004;5: 927–933. 15300249
31. Hayes EB, Is it time for a new yellow fever vaccine?Vaccine2010;28: 8073–8076. doi: 10.1016/j.vaccine.2010.10.01520971115
32. Gaspar LP, Mendes YS, Yamamura AM, Almeida LF, Caride E, et al. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods2008;150: 57–62. doi: 10.1016/j.jviromet.2008.03.00218420285
33. Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine2010;28: 3827–3840. doi: 10.1016/j.vaccine.2010.03.02320347059
34. Monath TP, Fowler E, Johnson CT, Balser J, Morin MJ, et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med2011;364: 1326–1333. doi: 10.1056/NEJMoa100930321470010
35. Appaiahgari MB, Pandey RM, Vrati S, Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines. Clin Vaccine Immunol2007;14: 1053–1055. 17596429
36. Sarwar UN, Novik L, Enama ME, Plummer SA, Koup RA, et al. Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial. PLoS One2014;9: e106240. doi: 10.1371/journal.pone.010624025264782
37. Steffensen MA, Jensen BA, Holst PJ, Bassi MR, Christensen JP, et al. Pre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient CD8 T-cell memory and recall responses. PLoS One2012;7: e34884. doi: 10.1371/journal.pone.003488422514686
38. Rampling T, Ewer K, Bowyer G, Wright D, Imoukhuede EB, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine—Preliminary Report. N Engl J Med2015;
39. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med2012;4: 115ra2. doi: 10.1126/scitranslmed.300292522218691